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ABSTRACT 
Objective: In vitro fertilization (IVF) is an important tool and it is widely used in the treatment of infertility. However, the failure rate is still high. 
Thus the study of the factors affecting the rate of success of IVF cycles is very important field of study. In the present study, the possible relationship 
between the Sirtuin-6 (SIRT6), a stress-responsive protein deacetylase, and the outcome of IVF was studied. SIRT6 also was correlated with 
hormone levels in women with IVF failure. 
Methods: Sixty women undergo IVF patients were participated in the study. Women group that had conceived from IVF are expressed as "pregnant 
group" while women who hadn’t are expressed as "failure group." All groups had same preparations and same treatment regimen. 
Results: Results revealed that there is an insignificant difference between pregnant and failure groups in serum SIRT6 level. The results showed a 
significant higher estradiol, and lower prolactin and antimullerian hormone in pregnant in comparing with failure group. Correlations studies 
indicated no significant correlation between SIRT6 and hormones in pregnant group, while there is a significant correlation between SIRT6 and 
estradiol hormone in the failure group. 
Conclusion: It can be concluded that serum SIRT6 level does not differ between women who had success or failure IVF. However, in women with 
failure, SIRT6 is correlated with estradiol level. 
Keywords: In vitro fertilization, Estradiol, SIRT6. 
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INTRODUCTION 
Infertility is the inability of a couple to achieve pregnancy over an 
average period of one year (in a woman under 35 y of age) or 6 mo 
(in a woman above 35 y of age) despite adequate, regular (3-4 times 
per week) unprotected sexual intercourse [1]. Infertility may also be 
referred to as the inability to carry a pregnancy to the delivery of a 
live baby.  
Infertility is a complex disorder with significant medical, psychosocial, 
and economic problems [2]. Hormonal imbalance is an important 
cause of anovulation. The disorder in the ovulation may lead to 
infertility. Hormonal irregularities that affect ovulation include 
hyperthyroidism, hypothyroidism, polycystic ovary syndrome and 
hyperprolactinemia [3]. Women with hormonal imbalance will not 
produce enough follicles to ensure the development of an ovule. 
Hormonal causes of female infertility involve ovulatory dysfunctions 
that may result from dysfunction of the hypothalamic-pituitary-
ovarian axis, peripheral endocrine glands, non-endocrine organs, or 
metabolic disorders [4]. Therefore, the study of the hormonal state is 
essential in the diagnosis of infertility and treatment. 
In vitro fertilization (IVF) is widely used and important tool in the 
treatment of infertility. IVF is a process by which an egg is fertilized 
by sperm outside the body. The process involves monitoring and 
stimulating a woman's ovulatory process, removing an ovum or ova 
(egg or eggs) from the woman's ovaries and letting sperm fertilize 
them in a liquid in a laboratory. The fertilized egg (zygote) is 
cultured for 2–6 d in a growth medium and is then implanted in the 
same or another woman's uterus, with the intention of establishing a 
successful pregnancy[5]. The cumulative percent pregnant was 
20.7% after the first IVF cycle, with nearly half pregnant within 
three and over two-thirds being pregnant within six cycles [6]. The 
low incidence of pregnancy in the first few cycles requires a lot of 
money, time and medical intervention. Thus, the study of the factors 
affecting the rate of success of IVF cycles is a very important field of 
study. In the present study, the possible relationship between the 
Sirtuin-6 (SIRT6), a stress-responsive protein deacetylase, and the 
outcome of IVF was studied in the present work. Furthermore, the 
correlation between SIRT6 and hormonal status in the women under 
IVF process is investigated. SIRT6 is a member of a highly conserved 
family of nicotinamide adenine dinucleotide (NAD+)-dependent 
deacetylase that it has both de-acetylation and adenosine 
diphosphate (ADP)-ribosylation activities. SIRT6 are implicated in 
age-related disorders or longevity [7]. Studies in mice have revealed 
that Sirt6 is essential for post-natal development and survival. Sirt6 
knockout mice, in which the gene encoding Sirt6 has been disrupted, 
exhibit a severe progeria, or premature aging syndrome, 
characterized by spinal curvature, lymphopenia and low levels of 
blood glucose [8]. SIRT6 plays diverse roles in regulating 
metabolism, cell proliferation, genome stability, and aging. Ovarian 
aging is thought to be characterized by a gradual decrease in both 
the number of follicles and the quality of oocysts. Ovarian reserve is 
indicated by the number of primordial follicles. Sirtuins including 
SIRT6 are present in the nucleus and cytoplasm of the oocysts and 
found to be a suppressor of the ovarian development [9]. However, 
the correlation of the SIRT6 with the result of IVF is not studied 
previously. The aim of the present study is to investigate the SIRT6 
level in women with failure and success IVF. The second aim is to 
correlate the serum SIRT6 concentration with some related 
hormones in women undergo IVF procedure. 
MATERIALS AND METHODS 
I-Subjects 
Sixty women undergo IVF patients participated in the study. Their 
age range was 27.35±7.61year. IVF cycles were conducted in the 
"Center of Fertility" in Al-Sadr Teaching Medical City in Najaf 
Governorate-Iraq during the period from June-August 2014. IVF 
process involves monitoring and stimulating a woman's ovulatory 
process, removing an ovum or ova from the woman's ovaries and 
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letting sperm fertilize them in a liquid in a laboratory. The fertilized 
egg (zygote) is cultured for 2–6 d in a growth medium and is then 
implanted in the same woman's uterus, with the intention of 
establishing a successful pregnancy. All the patients signed an 
informed consent form prior to the start of the study. The study was 
approved by the institutional review board at Kufa University, Iraq. 
The study excluded the patients with any obvious major systemic 
diseases including diabetes mellitus, hereditary diseases, or other 
endocrine disorders. Women were divided into two groups 
(pregnant and failure) according to the results of the IVF after few 
weeks of IVF process. Blood samples were collected from women 
before the operation. Women group that had conceived are 
expressed as "pregnant group" while women who hadn’t are 
expressed as "failure group." All groups had same preparations and 
same treatment regimen. 
Methods 
Serum hormones; Luteinizing hormone (LH), Follicle stimulating 
hormone (FSH), Estradiol (E2), Progesterone (PRG), Prolactin (PRL) 
were measured using ready for use ELISA kits supplied by 
Monobind®. Anti Müllerian Hormone (AMH) was measured using 
ready for use ELISA kits supplied by Ansh Labs, USA. SIRT6 ELISA kit 
was supplied from Cloud-Clone Corp., USA. 
Statistical analysis 
The distribution types of the variable results were examined by 
using the Kolmogorov-Smirnov test. Analysis results divided the 
variables into two types, namely, normally distributed variables and 
nonparametric variables, according to the statistical distribution. 
For the normally distributed variables, the results were expressed as 
mean±standard deviation. Pooled t-test was used for the comparison 
between the patients and control groups. Pearson's correlation 
coefficients (r) were used to estimate the correlation between 
parameters. For the nonparametric variables, the results were 
expressed as medians in addition to (mean±standard deviation). The 
Mann-Whitney U test was used for the comparison between the 
patients and control groups. Spearman's correlation coefficients (ρ, 
rho) were used to estimate the correlation between parameters. All 
statistical analysis was measured by using the SPSS Statistics 
Version 21 (2013) by IBM-USA.  
RESULTS  
1-Comparison between pregnant and failure groups 
Fig. 1 showed the serum SIRT6 level in pregnant and failure groups. 
Serum SIRT6 showed the insignificant difference between groups. 
 
 
Fig. 1: Serum SIRT6 level in pregnant and failure groups 
 
The results of hormones in pregnant and failure groups are 
presented in table (1). The results showed a significant higher 
estradiol (p=0.024), and lower PRL (p=0.002) and AMH (p=0.006) in 
pregnant in comparing with failure group. 
 
Table 1: Descriptive correlations among parameters in pregnant and failure groups expressed as mean standard deviation 
Parameters Pregnant Failure Significance 
LH (mlU/ml) 12.48±3.01 12.47±4.68 0.991 
FSH(mlU/ml) 6.28±2.71 6.58±4.72 0.764 
E2(pg/ml) 567.81±319.11 481.12±245.47 0.024* 
PRG(ng/ml) 10.96±6.56 20.30±69.62 0.470 
PRL(ng/ml) 8.94±4.39 15.72±4.89 0.002* 
AMH(ng/ml) 2.53±1.38 1.46±0.69 0.006* 
SAR6(ng/ml) 14.29±6.42 13.11±4.16 0.405 
*Significant difference (p<0.05) between pregnant and failure groups. 
 
Table 2: Correlations between SIRT6 and hormones in pregnant group 
 LH FSH E2 PRG PRL AMH BMI 
SIRT6 r -0.01 0.28 -0.14 0.02 0.16 -0.08 0.33 
p 0.94 0.14 0.43 0.91 0.40 0.64 0.08 
 
Table 3: Correlations between SIRT6 and Hormones in the failure group 
 LH FSH E2 PRG PRL AMH BMI 
SIRT6 r 0.09 -0.21 0.43* 0.25 -0.09 0.20 0.14 
p 0.65 0.25 0.02 0.18 0.60 0.30 0.46 
*Significant difference (p<0.05) between pregnant and failure groups.  
 
2-Correlations between SIRT6 and hormones in pregnant group 
The results in table 2 showed no significant correlation between 
SIRT6 and hormones in pregnant group 
3-Correlations among parameters in failure group 
The results in table 3 showed a significant correlation between 
SIRT6 and E2 hormone in the failure group. 
DISCUSSION 
The results in table 1 are in agreement with results of a study that 
showed that the higher pregnancy rates achieved is associated with, 
the higher E2 levels [10]. The levels of E2 in both groups are higher 
than the normal range in untreated women. This is due to the 
controlled ovarian hyperstimulation. The majority of IVF cycles 
demonstrated an increase in E2 levels post-hCG associated with the 
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improved clinical pregnancy rates and live births [11]. It is clear that 
supraphysiologic levels of E2 are inevitably attained during ovarian 
hyper stimulation owing to the development of multiple ovarian 
follicles, each contributing significantly to E2 production which can 
reach levels up to 10 times or more those found during spontaneous 
cycles. The effect of such supraphysiologic E2 levels on the outcome 
of IVF has remained controversial [12, 13]. E2 increases endometrial 
proliferation and uterine perfusion and because of this 
characteristic, estrogen improves the possibility of pregnancy. 
Although supraphysiologic E2 levels during ovarian stimulation for 
IVF represent one of the major deviations undergone by the female 
endocrine environment compared with the natural cycle, their 
significance for pregnancy achievement in IVF has only been 
assessed retrospectively [14,15]. On the contrary, three studies 
suggested a detrimental role of high E2 levels on the day of hCG 
administration for pregnancy achievement [16, 17].  
AMH belongs to the transforming growth factor-β (TGF-β) 
superfamily, and it is considered a local growth factor and a cellular 
differentiation factor [18]. In females, AMH is mainly secreted 
exclusively by the granulosa cells of ovarian early developing follicles 
from preantral and small antral follicles indicating AMH role in 
folliculo genesis [19]. AMH was an accurate marker for the occurrence 
of poor response to ovarian hyperstimulation with gonadotropins in 
IVF [20]. The correlation between AMH and IVF outcome. Several 
studies have revealed a significant positive correlation between AMH 
concentrations and pregnancy rate [21] and live birth rate [22,23]. 
However the results from the other studies [24] indicated that the 
predictive value for serum AMH in relation to clinical pregnancy rate, 
ongoing pregnancy rate and live birth rate is controversial [25]. There 
are some studies compare serum AMH and fluid follicle AMH on the 
predictive value of pregnancy rate, and the results are variable [26]. 
AMH is a predictor of IVF outcome [27]. AMH has been evaluated by 
several groups as a marker of ovarian response [18, 28]. AMH inhibits 
the initial recruitment of primordial follicles, through a paracrine 
effect (granulose cells-oocyte cross-talk) [29] and also inhibits the 
aromatase activity in granulose cells, thus reducing the production of 
E2 [30]. It is concluded that elevated AMH levels in either the serum or 
follicular fluid appeared to be predictive of clinical pregnancy [31]. 
Hyperprolactinemia is one of the major causes of infertility, brought 
about by inhibition of gonadotropin-releasing hormone (GnRH) or 
pulsatile GnRH secretion from the hypothalamus and impairment of 
LH output from the pituitary gland [32]. PRL within gonadotroph 
cells are controlled by dopamine, the main hypothalamic inhibitory 
regulator of PRL release in vivo, this specific actions of PRL within 
the gonadotroph and the cell signalling interactions that ultimately 
underlie hyperprolactinemia-induced infertility [32]; hyper-
prolactinemia can occur in physiological and pathological conditions 
[33] such as psychotic stress, severe mental illness or other causes, 
and the reproductive dysfunction affecting about one-third of 
infertile women [34]. Hyperprolactinemia causes infertility by 
increasing the release of dopamine from the hypothalamus which 
inhibits GnRH and thus gonadal steroidogenesis and eventual 
infertility [35]. Thus, the elevation of PRL in the failure group in 
comparing with a pregnant group consisted with the previous 
evidence. PRL is known to play a significant role in regulating 
ovarian functions, including folliculo genesis, steroid genesis, 
ovulation, and corpus luteum function [36, 37]. PRL levels are 
generally high in patients with ovulation and steroidogenesis 
disorders. It is reported that in the hyperprolactinemia, the rate of 
cleavage embryo and pregnancy rate was low. In addition, serum 
PRL levels after hCG administration are higher in pregnant women 
than in non-pregnant women after IVF [38]. In a study of rabbit 
oocytes, the addition of PRL to the culture fluid was found to 
promote oocyte maturity [39]. One of the other actions of PRL is to 
stimulate the ovarian production of PRG. That is required in the 
process of preparation for embryo implantation, and it is dependent 
on a continued estrogen and PRG secretion by the corpus luteum, 
which is supported by a functional pituitary during the first half of 
pregnancy in rodents [40]. Deficiency in the amount of PRG 
produced after ovulation may result in a uterine lining that is less 
able to have an embryo implant. Some women with this problem 
may see their period come a short time after ovulation [41]. 
The insignificant difference in SIRT6 between women with success 
IVF and women with failed IVF in table 1 and Fig.1 indicated a lack 
of a direct action of SIRT6 on the fertilization process. SIRT6 is 
involved in genomic DNA stability and repair, and crucial in 
metabolism and aging [42]. In animal studies, it is found that mice 
that over express SIRT6 had a long lifespan and associated with 
reduced level of serum insulin-like growth factor-1s and increased 
insulin-like growth factor binding protein-1 [43]. While, SIRT6-
deficient mice are small and they have severe metabolic defects, 
and they develop abnormalities that are usually associated with 
aging [44]. Over-expression of SIRT6 in mice had a protection 
effect against some metabolic impairment, including dyslipidemia 
[45]. Thus, the activation of SIRT6 might represent valuable 
therapeutic targets for aging and age-related diseases. However, a 
direct correlation between SIRT6 and all the above actions is not 
studied previously. In the present work, SIRT6 is not changed in 
the success or failure of IVF. 
The correlation between E2 and SIRT6 may indicate a possible effect 
of SIRT6 and E2 on the IVF failure but not in women who had 
successful IVF as seen in table 2 and 3. SIRT6 may regulate estrogen 
levels through peroxisome proliferator-activated receptor alpha 
(PPARα) and liver X receptor alpha (LXRα). A possible effect of 
SIRT6 on estrogen levels through LXRα and PPARα may explain the 
feminization effect seen for the over-expressed SIRT mice, and the 
estrogen levels may be correlated with SIRT6 levels in mice. Female 
mice with boosted levels of SIRT6 may have resulted in only a minor 
increase on the estrogen levels and no significant effect on the 
lifespan. The estrogen levels in SIRT6 over expressed mice are 
currently experimentally tested. The effect of SIRT6 over expression 
on downstream genes may be similar to their levels with higher-
than-average levels of estrogen which may drive female tissue 
tumors enriched in the correlated studies.  
The anti-correlated studies which correspond to a reverse effect of 
SIRT6 on downstream genes may be similar to lower-than-average 
levels of estrogen [46]. Histological analysis showed that caloric 
restriction mice displayed a significantly greater number of 
primordial follicles and less atretic ovarian follicles. The expression 
levels of SIRT6 were significantly decreased in the ovaries of aged 
mice and mice treated with chemotherapy. SIRT6 showed a 
significantly positive correlation with the numbers of primordial 
follicles. These results indicate that SIRT6 are closely related to 
ovarian reserve and may be a marker of ovarian aging [47]. SIRT6 
contain deacetylase activity [48] and has a DNA repair activity via 
interaction with different molecules [49]. Estradiol affects the 
biochemical components of the reproductive tracts and gonads by 
increasing lipids contents that have negative effects on the fertility 
[50]. SIRT6 also has same effects on the lipid metabolism. These 
facts may interpret the findings of the present study. Further 
investigation in a larger sample size is required to obtain more 
persistent conclusion about the role of SIRT6 in the IVF failure. 
CONCLUSION 
Serum SIRT6 levels is not differing between women who had success 
or failure IVF. However, in women with failure, Sirt6 is correlated 
with E2 level. 
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